Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0; the study page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T20:43:09.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error, replacing the study content with a simple error layout and a Home button. The detailed study information and navigation are no longer visible due to access restrictions.
    Difference
    16%
    Check dated 2026-09-19T19:21:58.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The study record now includes information about sharing individual participant data (IPD), including policy details, the plan for IPD sharing, and a URL for the policy.
    Difference
    0.4%
    Check dated 2026-09-12T18:03:45.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    A funding line for 2019 (U.S. NIH Grant/Contract) has been added. The revision history now shows Revision: v3.6.6, replacing the previous v3.6.5 entry.
    Difference
    0.0%
    Check dated 2026-08-29T18:56:30.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The input indicates no changes to add or remove on the page; thus the page content remains as currently published.
    Difference
    0.0%
    Check dated 2026-08-22T16:27:09.000Z thumbnail image
  8. Check
    63 days ago
    Change Detected
    Summary
    A new Publication entry was added under Publications: Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaci D, Augustin M, Puig L, Daamen C, Li J, Alio A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials, Am J Clin Dermatol, 2026 Aug 7 (online ahead of print).
    Difference
    0.0%
    Check dated 2026-08-15T12:15:29.000Z thumbnail image

Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.